ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Verastem Inc

Verastem Inc (VSTM)

4.48
-0.02
(-0.44%)
Closed December 14 4:00PM
4.48
0.00
(0.00%)
After Hours: 6:55PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
4.48
Bid
4.49
Ask
5.12
Volume
516,289
4.31 Day's Range 4.63
2.10 52 Week Range 14.22
Market Cap
Previous Close
4.50
Open
4.4003
Last Trade
22
@
4.49
Last Trade Time
Financial Volume
$ 2,296,048
VWAP
4.4472
Average Volume (3m)
1,027,935
Shares Outstanding
44,506,526
Dividend Yield
-
PE Ratio
-2.28
Earnings Per Share (EPS)
-1.96
Revenue
-
Net Profit
-87.37M

About Verastem Inc

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/... Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Verastem Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VSTM. The last closing price for Verastem was $4.50. Over the last year, Verastem shares have traded in a share price range of $ 2.10 to $ 14.22.

Verastem currently has 44,506,526 shares outstanding. The market capitalization of Verastem is $200.28 million. Verastem has a price to earnings ratio (PE ratio) of -2.28.

VSTM Latest News

Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a...

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Completed rolling NDA submission for avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer in October 2024 Company seeking accelerated approval and...

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments Company seeking accelerated approval and priority review of its NDA submission in patients with KRAS...

Verastem Oncology to Participate in Upcoming Investor Conferences

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.77-14.66666666675.256.054.3857876645.15238515CS
40.358.474576271194.136.053.7210714794.81921016CS
121.6558.30388692582.836.052.5410279353.85700214CS
260.9326.19718309863.556.052.17991513.44380172CS
52-2.61-36.81241184777.0914.222.15978694.34763696CS
156-23.384-83.921906402527.86429.42.1111746911.49471687CS
260-11.96-72.749391727516.4459.222.1206157421.88366442CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WKEYWISeKey International Holdings AG
$ 7.84
(139.02%)
75.53M
IPHAInnate Pharma SA
$ 3.00
(93.55%)
13.59M
AVLDirexion Daily AVGO Bull 2X Shares
$ 33.67
(48.92%)
658.55k
LOOPLoop Industries Inc
$ 1.8092
(47.09%)
82.56M
AVGXDefiance Daily Target 2X Long AVGO ETF
$ 31.49
(46.67%)
3.55M
RPTXRepare Therapeutics Inc
$ 1.765
(-55.54%)
4.7M
INOInovio Pharmaceuticals Inc New
$ 2.31
(-38.56%)
9.86M
XXII22nd Century Group Inc
$ 0.048
(-34.69%)
42.23M
FLGCFlora Growth Corporation
$ 1.30
(-34.34%)
4.14M
WTOUTime Limited
$ 0.281
(-32.74%)
3.79M
NVDANVIDIA Corporation
$ 134.25
(-2.25%)
228.17M
SOUNSoundHound AI Inc
$ 16.905
(23.66%)
158.74M
TRUGTruGolf Holdings Inc
$ 0.6794
(30.93%)
138.19M
RGTIRigetti Computing Inc
$ 7.155
(19.85%)
122.67M
AVGOBroadcom Inc
$ 224.80
(24.43%)
117.74M

VSTM Discussion

View Posts
axelvento axelvento 2 months ago
stay tuned-----The oral presentation will include updated safety and efficacy data from the RAMP 201 trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC), including overall response rate, progression free survival, and duration of response.

Company to host investor conference call and webcast on October 17, 2024, at 4:30 pm EDT
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
VSTM under $3
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
VSTM new 52 week low
πŸ‘οΈ0
Termite7 Termite7 7 months ago
https://www.verastem.com/research/pipeline/ Good pipeline!!!
πŸ‘οΈ0
TheFinalCD TheFinalCD 7 months ago
For those who are curious why $VSTM is down 60% on premarket, being 50% yesterday afterhours, despite positive RAMP 205 data (High ORR)

https://x.com/WallStDayTrader/status/1793988987092369420
https://x.com/Dogtor01416800/status/1793983764386939192
👍️ 1
TheFinalCD TheFinalCD 7 months ago
4.75 NOW VSTM over $18
πŸ‘οΈ0
pmach64 pmach64 7 months ago
Brutal morning sell off after what appeared to be good news.
πŸ‘οΈ0
tw0122 tw0122 7 months ago
VSTM over $18
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
VSTM over $10
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
Read about it at 3.00 it looks like.
πŸ‘οΈ0
muchogusto muchogusto 1 year ago
Worth reading
https://www.onclive.com/view/avutometinib-defactinib-combo-generates-early-efficacy-signals-in-low-grade-serous-ovarian-cancer
πŸ‘οΈ0
Harbor6460 Harbor6460 1 year ago
It’s death after a RS. Wait for 4.00 or way under. Then Good risk reward
πŸ‘οΈ0
muchogusto muchogusto 1 year ago
So, what is next for VSTM in terms of catalysts and results? Any upcoming data points? Is it now free from funding worries and free to focus on producing results? Tartia, your input would be appreciated.
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
Happy I hit and run. I would consider this at under 4.00
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
They definite are diluting. They need money. But in long run great for shareholder
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
highest volume in history -insert dd-
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
Yep
πŸ‘οΈ0
knrorrel knrorrel 2 years ago
nice
πŸ‘οΈ0
The Night Stalker The Night Stalker 2 years ago
oh my
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Looks like dilution
πŸ‘οΈ0
KeepOn KeepOn 2 years ago
Looks like real support at a dollar. Could be ready for next leg.
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Added the dip
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
I post so others can ride with me to the victory circle so to speak.
I really like it when peeps get a good run.
πŸ‘οΈ0
Invest-in-America Invest-in-America 2 years ago
VSTM: Well, Capt. T-N, you certainly scored MONSTER TIME on this one today, Dude!!! (EASY money for you, or WHAT, Bro!!! CONGRATS!!!)
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
Halted?
πŸ‘οΈ0
jchords jchords 2 years ago
Nice call
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Okay nice run folks
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
.75 comin up

1.00 soon
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
LV2 still looks real thin
.75 ?
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Really Good Friday here
πŸ‘οΈ0
power11 power11 2 years ago
WHAT NEWS ??????
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
I’d be nice waking up to thirty bucks a share from this level
πŸ‘οΈ0
shurtha2000 shurtha2000 2 years ago
This kind of news you can skip PHASEIII and go straight to approval
πŸ‘οΈ0
Tartiaboy Tartiaboy 2 years ago
Next week it should run strong.
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
This news is very positive
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Peeps see double tops and think sell
Just bust through it
πŸ‘οΈ0
Tartiaboy Tartiaboy 2 years ago
You would think.
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Break past .52 come on
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
Insiders are buying options. Time to load imo. Could see 2.00-3.00 like nothing
πŸ‘οΈ0
SaltyOne SaltyOne 2 years ago
I'm with you on this one and so are the Baker Bros
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
Never seen a board that nobody post wtf. Lol. We got things coming imo
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
2 million volume yesterday. That’s a fund imo. I told you this was coming. Price of a stock does not reflect market value. This combo of drugs is a monster. I see 5-15.00 by Jan 2025
πŸ‘οΈ0
Tartiaboy Tartiaboy 2 years ago
In addition to the progress with avutometinib + defactinib in LGSOC ONCT is moving two KRAS-G12C projects forward: avutometinib + sotorasib and avutometinib + adagrasib in KRAS-(G12C) NSCLC. Preclinical data suggests that we should see synergy with these combinations. I believe that the avuto + soto initial readout should happen at any time and this will be a big deal if the data is encouraging. In the preclinical data VSTM demonstrated that the synergistic effect of avutometinib + a G12C inhibitor was further enhanced with the addition of defactinib. I hope that they advance this G12C program with both the doublet and the triplet approach.

Clinical progress with the LGSOC program and the KRAS-G12C programs justify a much higher market cap than we have now. Any success with pancreatic cancer would be a total game-changer. The LGSOC and KRAS-G12C programs and low market cap provide a low risk opportunity to be in on the big prize which is Pancreatic cancer.
πŸ‘οΈ0
Tartiaboy Tartiaboy 2 years ago
The RAMP201 and FRAME data for LGSOC is excellent so far. We should have final data readout in about 18 months (IMO). This data is expected to support an AA filing with the FDA for LGSOC. The current PPS does not reflect the significance of this. In addition, we have near term pending data on RAMP203 for RAS(G12C) NSCLC. Positive results with RAMP203 will further enhance value and help establish Avutometinib as a valid approach to RAS pathway cancers.

As an aside, I have my eyes on Akena's RAF:MEK clamp which may be even better than Avutometinib. The only problem is that Akena's molecule is several years behind Avuto in development.
πŸ‘οΈ0
Tartiaboy Tartiaboy 2 years ago
I think that anyone interested needs to follow-up reading this PR by listening to the webcast presentation. It provides a more granular and encouraging overview than the PR alone does. I felt much more encouraged after hearing the overview and seeing the slides.

For instance the 28% ORR is interim data, not fully matured data. If one includes the 3 unconfirmed PRs the ORR is 38%. That's very good. If approved there will be TWO drugs approved.
πŸ‘οΈ0
DrHarleyboy DrHarleyboy 2 years ago
Regulatory Update Following Type B FDA Meeting on LGSOC Program

A recent FDA meeting was held to discuss the encouraging results to date of the ongoing RAMP 201 trial evaluating avutometinib ± defactinib among patients with recurrent LGSOC, confirm the go forward treatment regimen selection and discuss the regulatory path forward. The combination of avutometinib with defactinib has been selected vs monotherapy as the go forward treatment in all recurrent LGSOC regardless of KRAS status, acknowledging the demonstrated contribution of defactinib.

The Company intends to include mature data from RAMP 201, the Verastem sponsored clinical trial, and the FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust to potentially support filing for accelerated approval. Both studies are evaluating avutometinib and defactinib in patients with recurrent LGSOC. The Company is in ongoing discussions with the FDA on the confirmatory study and plans to provide an update after agreement with the FDA. Continued enrollment in the combination arm of RAMP 201 is planned to expand the clinical experience in anticipation of initiation of a confirmatory study.

β€œWe appreciate the productive and ongoing discussions with the FDA regarding the progress of our LGSOC program, including the alignment around key next steps as part of our breakthrough therapy designation,” said Brian Stuglik, CEO of Verastem Oncology. β€œWith the encouraging results of the RAMP 201 Part A interim analysis and the FRAME study, we will work expeditiously to prepare to file for an accelerated approval that encompasses the totality of the data from both trials as well as progress on the confirmatory study.”

https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-announces-positive-data-and-regulatory-update
πŸ‘οΈ0
Tartiaboy Tartiaboy 2 years ago
I already one a nice chunk. Listened to the webcast. Data looks very impressive. Open to discussing it.
πŸ‘οΈ0
DrHarleyboy DrHarleyboy 2 years ago
Ramp 201 Data Updated, and a Private Placement secured.

BUY
πŸ‘οΈ0
Harbor6460 Harbor6460 2 years ago
Looks like Big mews coming in next 3-6 months
πŸ‘οΈ0
DrHarleyboy DrHarleyboy 2 years ago
Well, not time like the present to start a position, I doubt it can get much worse except go to $0.....

Still waiting on some results that will make or break this tiny Biotech.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock